A new report by visiongain forecasts that overall sales of 3D printing technology and products for healthcare will achieve revenues of $2854 million in 2020. Sales will expand from 2016 to 2026 as the demand for personalised healthcare products increases. An ageing population, in addition to increasing recognition of the effectiveness of 3D printed products over traditional ones, will create high, rising demand for additive manufacturing.

Those predictions and others appear in 3D Printing for Healthcare, Trends, R&D and Revenue Forecasts 2016-2026: Explore Dental Products, Medical Implants, Pharmaceuticals, Bio-printing and Other Uses for Additive Manufacturing. That updated, expanded study appeared in February 2016.

Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations explore potentials of industries and markets in healthcare and other fields.

The new investigation analyses events, prospects and sales opportunities shaping the development, production and marketing of 3D printing for applications in healthcare worldwide. That analysis shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of leading companies providing technology and products, assessing their potentials from 2016. Healthcare industries will provide a substantial proportion of revenue in 3D printing alongside aerospace, defence and consumer goods, the study finds.

Robert King, a pharmaceuticals and healthcare industry analyst in visiongain, said: “Our survey predicts that there will be rapid growth for the global 3D printing for healthcare market from 2016-2020, after which time revenue growth rates will slow to 2026 as the technology becomes more established. However, growth will still remain positive year on year for the duration of the forecast. The revenue expansion will be sustained by a strong R&D pipeline of technology and products, some of which will make the transition to commercial launch. The outlook for the market over the forecast period is promising, with a predicted compound annual growth rate of 20.7% from 2015 to 2026.

“In 2015, dental products formed the leading product submarket, accounting for 57.29% of the product market, our study finds. However, by 2018 the medical implants submarket will overtake it due to a rapid increase in demand for personalised orthopaedic implants. Bio-printing and other uses will make up the rest of the product market share.

“Adoption of 3D printing technology in the healthcare industry will be significant across our forecast period, with a particular emphasis on the use of 3D printed dental and medical implants. Technology and products for 3D printed pharmaceuticals and bio-printed tissues will become prominent, and more so after 2026.”

That updated investigation shows revenue predictions at overall world market, submarket and national level. Visiongain includes seven interviews with authorities in that field.

First that work shows individual revenue predictions to 2026 for six submarkets at world level:

• Products – with sub-forecasts for dental products, medical implants, bio-printed tissue and other applications
• Technology – processes for supporting those developments.

The analyses also cover the most prominent 11 national markets for 3D printing healthcare applications, with other data and discussions:

• United States (US)
• Japan
• Germany, France, UK, Italy and Spain (EU5 countries)
• Brazil, Russia, India and China (BRIC group).

Leading organisations in 3D printing for healthcare – technology providers and product innovators – are included. Sections show financial information, product portfolios and recent mergers and acquisitions, among other details. Companies the study discusses include these:

• Stratasys
• 3D Systems
• EOS
• Tissue Regeneration Systems
• Oxford Performance Materials
• Tronrud Engineering
• Arcam AB
• Organovo
• Bio3D Technologies
• Aprecia Pharmaceuticals Company.

3D Printing for Healthcare, Trends, R&D and Revenue Forecasts 2016-2026 adds to visiongain’s reports and contract research on industries and markets in healthcare. That portfolio covers pharmaceuticals, biotechnology, medical devices, diagnostics and outsourced services.